Tomligisiran (sodium)
Tomligisiran sodium is a siRNA in JNJ-3989 (JNJ-73763989) . JNJ-3989 is comprised of 2 siRNAs (Daplusiran and Tomligisiran), that target hepatitis B virus (HBV) mRNAs for degradation, thereby inhibiting HBV replication.
Product Specifications
UNSPSC
12352208
Target
HBV
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Smiles
[Tomligisiran(sodium)]
References & Citations
[1]Kakuda TN, Halabi A, Klein G, et al. Pharmacokinetics of JNJ-73763989 and JNJ-56136379 (Bersacapavir) in Participants With Moderate Hepatic Impairment. J Clin Pharmacol. 2023;63 (6) :732-741.|[2]Li H, Niu X, Zhang Y, et al. Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ-73763989 in Healthy Chinese Adult Participants. Clin Pharmacol Drug Dev. 2023;12 (2) :175-180.|[3]Gane E, Yuen MF, Kakuda TN, et al. JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos (t) ide analogue in patients with chronic hepatitis B. Antivir Ther. 2022;27 (3) :13596535221093856.
Shipping Conditions
Room temperature
Scientific Category
Oligonucleotides
Clinical Information
Phase 2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC741706-100 1x 100 µL
S100B (Astrocyte and Melanoma Marker) (S100B/1706R), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880784-100 1x 100 µL
CD56 / NCAM (NCAM1/784), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 